Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) is an acquired, inflammatory eye condition affecting the retina, retinal pigment epithelium (pigmented layer of the retina), and choroid. It usually affects both eyes and is characterized by multiple, yellow-white lesions in the back of the eye. The condition can significantly impair visual acuity if the macula is involved. APMPPE typically resolves on its own in weeks to months. While the cause is unknown, about a third of cases appear to develop after a flu-like illness. Non-ocular symptoms are uncommon, but cerebral vasculitis can be present and may cause permanent and/or severe neurological complications.
Biomarker and diagnostic research for acute posterior multifocal placoid pigment epitheliopathy has been reported in the published literature.
No clinical trials have been registered for acute posterior multifocal placoid pigment epitheliopathy.
48 publications have been identified in PubMed for acute posterior multifocal placoid pigment epitheliopathy. Research spans Case Report / Case Series (48%), Review / Meta-Analysis (19%), and Other (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 23 | 48% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 9:40 AM UTC
Genetic and Rare Diseases Info Center
Common questions about acute posterior multifocal placoid pigment epitheliopathy
Research summaries
9 |
19% |
Other research | 4 | 8% |
Testing and diagnosis research | 4 | 8% |
Disease patterns and progression | 4 | 8% |
Clinical study results | 3 | 6% |
Laboratory research | 1 | 2% |
Mount GR (2026). [PMID: 32491777](https://pubmed.ncbi.nlm.nih.gov/32491777/). *Unknown Journal*. [Review / Meta-Analysis]
De Simone L (2026). [PMID: 41784636](https://pubmed.ncbi.nlm.nih.gov/41784636/). *Ocul Immunol Inflamm*. [Diagnostic / Biomarker]
Invernizzi A (2026). [PMID: 42150663](https://pubmed.ncbi.nlm.nih.gov/42150663/). *Am J Ophthalmol*. [Diagnostic / Biomarker]
Hooper CY (2026). [PMID: 40706821](https://pubmed.ncbi.nlm.nih.gov/40706821/). *Surv Ophthalmol*. [Review / Meta-Analysis]
Boyce TM (2026). [PMID: 42063291](https://pubmed.ncbi.nlm.nih.gov/42063291/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Fricker J (2026). [PMID: 42008796](https://pubmed.ncbi.nlm.nih.gov/42008796/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Feo A (2026). [PMID: 41490810](https://pubmed.ncbi.nlm.nih.gov/41490810/). *Am J Ophthalmol*. [Review / Meta-Analysis]
Samalia PD (2026). [PMID: 41642701](https://pubmed.ncbi.nlm.nih.gov/41642701/). *Am J Ophthalmol*. [Other]
Bianco L (2026). [PMID: 41861897](https://pubmed.ncbi.nlm.nih.gov/41861897/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Belletti M (2026). [PMID: 41481499](https://pubmed.ncbi.nlm.nih.gov/41481499/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
AI-curated news mentioning acute posterior multifocal placoid pigment epitheliopathy
Updated Jul 14, 2026
A study highlights the occurrence of macular neovascular membranes as a late complication of acute posterior multifocal placoid pigment epitheliopathy (APMPPE), treated effectively with intravitreal aflibercept. This research contributes to understanding the long-term management of APMPPE.